Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Describing An Investigational Drug On Your Website? Don’t Be Definitive About The Data, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA issues untitled letter to CBA Research Inc. for touting the safety and efficacy of CBT-1 as a cancer therapy on the company website although the agency has yet to complete review of an NDA for the drug.

You may also be interested in...

IND Promotion Quandary Again Trips Up Burzynski Research Institute

The institute has come under scrutiny in the past for how it describes its investigational cancer products, but more mainstream oncology companies have also been cited for jumping the gun with promotional claims for products FDA hasn’t yet approved.

CEL-SCI Warning Letter Shows Pitfalls Of Website Presentations Of Investigational Drugs

Website suggested that the unapproved cancer immunotherapy was safe and effective, FDA says.

Cancer Drug Website Draws FDA's Ire For Promoting A Product In Clinical Trials

Keryx Biopharmaceuticals is cited for claiming on its website that its investigational oncology drug perifosine is safe and effective.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts